OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Bryant on the Background For Investigating Germline DNA Repair Mutations in PDAC

February 2nd 2024

John Michael Bryant, MD, discusses the effects of germline DNA repair mutations on radiosensitivity in patients with pancreatic ductal adenocarcinoma.

Dr Yaeger on the Background of the CodeBreaK 101 Trial in mCRC

February 2nd 2024

Rona Yaeger, MD, discusses the rationale for launching an expansion cohort study based on findings from the CodeBreaK 101 study.

Truong on the Rationale for Investigating ERK2 Substrate Binding Modalities in MPNs

February 2nd 2024

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.

Dr Sharma on Questions Regarding the Optimal Use of Triplet Therapies in HSPC

February 2nd 2024

Janaki Neela Sharma, MD, discusses data with triplet therapies in patients with hormone-sensitive prostate cancer.

Dr Crafton on the Use of Mirvetuximab Soravtansine in Ovarian Cancer

February 2nd 2024

Sarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.

Dr Hafez on the Influence of Biomarker Expression on Adjuvant T-DM1 Use in HER2+ Breast Cancer

February 1st 2024

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

Dr Arner on the Role of SETD2 Loss in Tumor Growth and Metastasis in ccRCC

February 1st 2024

Emily Arner, PhD, discusses research on the role of SETD2 loss in metastatic clear cell renal cell carcinoma ccRCC.

Dr Mascarenhas on the Use of Selinexor in Myelofibrosis

February 1st 2024

John Mascarenhas, MD, discusses the use of selinexor with ruxolitinib in JAK inhibitor–naive myelofibrosis, highlighting the phase 2 XPORT-MF-044 trial

Dr Garmezy on the Impact of Combination Regimens on Outcomes and Quality of Life in Patients With RCC

February 1st 2024

Benjamin Garmezy, MD, discusses the impact of frontline combination regimens on patient outcomes in patients with renal cell carcinoma.

Dr McAndrew on the Implications of the PHERGain Study in HER2+ Breast Cancer

February 1st 2024

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

January 31st 2024

Jorge J. Castillo, MD, discusses the efficacy of treatment with iopofosine I 131 in patients with Waldenström macroglobulinemia.

Dr Hashmi on Real-World Teclistamab Use in Relapsed/Refractory Multiple Myeloma

January 31st 2024

Hamza Hashmi, MD, discusses a real-world study of the efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma.

Dr DeBernardo on the Role of PARP Inhibitors in Frontline Ovarian Cancer

January 31st 2024

Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.

Dr Battiwalla on Outpatient CAR T-Cell Therapy Administration in Hematologic Malignancies

January 31st 2024

Minoo Battiwalla, MD, discusses findings from a study of outpatient care after CAR T-cell therapy in patients with hematologic malignancies.

Dr Kyriakopoulos on the Initial Activity and Safety of Masofaniten Plus Enzalutamide in mCRPC

January 31st 2024

Christos Kyriakopoulos, MD, discusses data from a phase 1/2 study of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.

Dr Vose on Mitigating Epcoritamab-Associated CRS and Neurologic Toxicities in R/R DLBCL

January 30th 2024

Julie M. Vose, MD, MBA, discusses the mitigation of toxicities with epcoritamab in an optimization cohort of patients with relapsed/refractory DLBCL.

Dr Danilov on Using MRD Status to Predict Outcomes in Hematologic Malignancies

January 30th 2024

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.

Dr Siegel on the Use of Carfilzomib/Iberdomide/Dexamethasone Therapy in Multiple Myeloma

January 30th 2024

David Samuel Dicapua Siegel, MD, discusses the potential use of carfilzomib, iberdomide, and dexamethasone in newly diagnosed multiple myeloma.

Dr Wierda on the Genomic Evolution of Pirtobrutinib in Pretreated CLL

January 30th 2024

William G. Wierda, MD, PhD, discusses the genomic evolution of pirtobrutinib in pretreated chronic lymphocytic leukemia.

Caprice on Racial and Ethnic Disparities in Transplant Outcomes in Hematologic Malignancies

January 30th 2024

Teresa Caprice, PA-C, discusses the use of post-transplant cyclophosphamide to address disparities in transplant outcomes in racial and ethnic populations.